Several lines of evidence have shown that long non-coding RNAs (lncRNAs) are dysregulated in many diseases. nevertheless, the biological relevance of the lncRnAs in papillary thyroid carcinoma (ptc) has not been fully explored. We demonstrated that CTC was a negative regulator of PTC cell migration and invasion in vitro and in vivo. We found that microRNA-146 (miR-146) is an inhibitory target of CTC. We then demonstrated that CTC functioned as a miR-146 decoy to de-repress expression of KIT. Further study demonstrated that CTC modulated the progression and chemoresistance of PTC cells via miR-146 and KIT. The analysis of hundreds of clinical specimens revealed that CTC and KIT levels were downregulated, whereas miR-146 levels were greater in PTC tissues than in normal thyroid. Their expression levels correlated with one another. In conclusion, CTC functions as a competing endogenous RNA to inhibit the progression and chemoresistance of PTC cells, and identifies CTC serve as a potential therapeutic agent to suppress PTC progression.
In this study, we identified a novel lncRNA, lncRNA-CTC (CTC), that regulates the proliferation and invasion of PTC cells. We also demonstrated that CTC directly binds with miR-46 and functions as an miRNA decoy to regulate KIT expression.
Results

LncRnA ctc inhibits the proliferation and invasion of papillary thyroid cancer cells. Because
miR-146 was consider as a potential molecular biomarker in PTC 25 , we suspect that some lncRNAs regulate PTC cell via miR-146. To verify our conjecture, DIANA TOOLS (a human lncRNA target prediction tool) was used to screen lncRNAs, which have potential ability to associate with miR-146. According to the results from DIANA TOOLS, ten high-scoring candidate lncRNAs were chosen for subsequent study. Next, we compared expression levels of these potential lncRNAs in PTC tissues and the corresponding adjacent normal tissues (ANT). As shown in Supporting Fig. 1 , lncRNA-CTC (CTC) was expressed at lower levels in PTC tissues than in ANT, and CTC was chosen for further study. CTC is located at chromosome 19: 27,793,496-27,799 ,403 with the transcript length 5908 nt (ENST00000592404). ORF (Open Reading Frame) Finder software shown that the potential ORFs for CTC were totally shorter than 480 bp (Supporting Fig. 2A ). CPC (Coding Potential Calculator) software was used to identify the coding potential of CTC, and results showed that each transcript of CTC was unable to code (Supporting Fig. 2B ). In vitro translation experiments were performed to verify these software prediction results. As shown Supporting Fig. 2C , protein bands for CTC were not observed. The 180 kD protein band of DNMT1 was used for positive control. A full-length CTC was identified using RACE experiments (Supporting Fig. 2D ). The localization of CTC was also evaluated. We found that CTC was localized in both the cytoplasm and the nucleus (Supporting Fig. 2E ).
We next examined the potential function of CTC in the proliferation and invasion of PTC cells. To do this, we constructed overexpression plasmids and two specific small interfering RNAs (siRNAs). qRT-PCR analysis indicated that siRNA #1 and #2 inhibit the expression of CTC (Supporting Fig. 3 ). PTC cells proliferation rates were decreased by CTC overexpression plasmids (Fig. 1A) . Conversely, knockdown of CTC increased the proliferation rates of PTC cells (Fig. 1B ). In line with these data, CTC overexpression promoted PTC cells migration and invasion, whereas knockdown of CTC resulted in the inhibition of PTC cell migration and invasion ( Fig. 1C -F). To determine whether CTC affect tumorigenicity in vivo, an additional experiment was performed. Nude mice were subcutaneously injected with CTC knockdown or control cells. We found that, compared with control mice, CTC knockdown mice exhibited higher tumor growth; however, there were no effects on body weight ( Fig. 1G-I) . Further experiments confirmed that CTC expression levels were higher in control mice than in CTC knockdown mice (Fig. 1J ). These in vivo and in vitro data suggest that CTC induces the proliferation of PTC.
CTC binds to miR-146 and represses its expression.
Because miR-146 is a potential target of CTC, we investigated whether CTC binds to miR-146. To do this, wild-type (WT) CTC were cloned into firefly luciferase reporter plasmids. One mutation was generated from WT CTC at the predicted target site to miR-146 ( Fig. 2A) . The luciferase activity assay showed that pre-miR-146 inhibited WT CTC luciferase activity, but not the luciferase activity of mutant CTC (Fig. 2B ). Consistent with this result, anti-miR-146 induced WT CTC luciferase activity, but the mutant CTC did not ( Fig. 2C ). To determine whether miR-146 was indeed a target of CTC, we tested the ) were co-transfected with either lncRNA CTC WT or mutants and pre-miR-146 or pre-control. Luciferase activities were measured after 48 h using a dual-luciferase assay kit and normalized to Renilla luciferase. (C) Experiments were performed similar to those in (B), except indicated anti-control or anti-miR-146 were used. (D) TPC-1 cells were transfected with indicated plasmid for 48 h prior to qRT-PCR assay. (E) TPC-1 cells were co-transfected with either lncRNA CTC WT or mutants and anti-miR-146 or anti-control for 48 h prior to pull-down assays. (F) TPC-1 cells (left panel) or KAT-5 cells (right panel) were co-transfected with either lncRNA CTC WT or mutants for 48 h prior to qRT-PCR assay. (G) Experiments were performed similar to those in (F), except indicated siRNAs were used. (H) TPC-1 cells (left panel) or KAT-5 cells (right panel) were transfected with pre-miR-146 or pre-control for 48 h prior to qRT-PCR assay. (I) Experiments were performed similar to those in (B), except indicated anti-control or anti-miR-146 were used. In the qRT-PCR experiments, the vector control was designated as 1. Bar graphs present means ± SD, n = 3 (**P < 0.01; *P < 0.05). efficacy of CTC WT and mutant expression ( Fig. 2D ). Pull-down assays were performed to investigate whether CTC bound miR-146. We found that WT CTC, but not mutant CTC, bound miR-146 ( Fig. 2E ). Anti-miR-146 abolished miR-146 precipitation ( Fig. 2E ). We next investigated the role of CTC on miR-146 expression. As shown Fig. 2F , CTC WT decreased miR-146 expression, whereas mutant CTC had no effect. Conversely, CTC knockdown induced miR-146 expression ( Fig. 2G ). Interesting, neither overexpression nor knockdown of miR-146 had an effect on CTC expression levels ( Fig. 2H ,I), suggesting that miR-146 was downstream of CTC. These results suggest that CTC associates with miR-146, and suppress its expression.
CTC suppress the proliferation and invasion of PTC cells through miR-146. Because CTC regu-
lates the proliferation and invasion of PTC cells and CTC binds to miR-146, we next examined the role of CTC binding of miR-146 in the proliferation of PTC cells. As shown in Fig. 3A , pre-miR-146 abolished the effect of CTC in the proliferation of PTC cells. Conversely, anti-miR-146 and the CTC overexpression plasmid synergistically inhibited PTC cell proliferation (Fig. 3B ). The effect of the CTC/miR-146 signaling pathway on PTC cell proliferation was further evaluated using CTC siRNAs. Pre-miR-146 induced the effect of the CTC siRNA on the proliferation of PTC cells (Fig. 3C ). Anti-miR-146 abolished the effect of CTC siRNA on the proliferation of PTC cells ( Fig. 3D ). Similar results were also obtained in cell migration and invasion assays ( Fig. 3E-H ). Together, these data demonstrate that CTC regulated the migration and invasion of PTC cells, and that miR-146 is a downstream molecule in the CTC-regulated pathway.
CTC suppress the proliferation and invasion of PTC cells through KIT.
Because KIT is a target of miR-146, the influence on CTC inhibited migration and invasion of PTC cells were evaluated. First, the role of CTC on KIT expression was investigated. We found that CTC induced KIT mRNA and protein expression in a time-dependent manner ( Fig. 4A ). Similarly, a dose-dependent increase in KIT expression was also observed in PTC-1 cells, in which were transfected with CTC overexpression plasmid for incremental concentrations (Fig. 4A ). We next determined the effect of miR-146 on CTC-regulated KIT expression. Pre-miR-146 inhibited CTC-induced KIT mRNA and protein expression levels, whereas anti-miR-146 and CTC overexpression plasmid synergistically induced KIT expression ( Fig. 4C,D) .
To test whether KIT affect CTC regulated PTC cell proliferation, migration and invasion, we designed two siRNA plasmids for KIT (KIT siRNA #1 and #2), and tested the efficiency of those siRNAs ( Fig. 4E ). MTT assays suggested that overexpression of KIT induced the effect of the CTC overexpression plasmid on the proliferation of PTC cells ( (Fig. 5C,D) . Next, we evaluated whether CTC regulated cell chemoresistance via KIT. Results shown that overexpression of KIT induced CTC-inhibited chemoresistance; conversely, knockdown of KIT reduced CTC-inhibited cell chemoresistance to 5-Fu and Dox (Fig. 5E,F) . Similarly, overexpression of KIT abrogated inhibition of chemoresistance by CTC (Fig. 5G ). Knockdown of both CTC and KIT synergistically induced chemoresistance (Fig. 5H ). Collectively, these results suggest that CTC decreases the resistance of CRC cells to chemotherapy drugs via the miR-146/KIT axis.
Expression of CTC, miR-146, and KIT in clinical samples. To elucidate whether CTC/miR-146/KIT
axis could be an important pathway to decide the outcome of PTC, we first analyzed the expression of CTC, miR-146 and KIT in five normal thyroid (NT) tissues and seven human PTC cell lines (K1, K2, KTC-1, KAT-5, TPC-1, BHP5-16, and BCPAP). The expression levels of CTC and KIT was downregulated in PTC cell lines than NT tissues, whereas miR-146 expression was upregulated in PTC cell lines than NT tissues ( Fig. 6A-C) . Further studies were performed to explore clinical relevance in clinical samples by comparing CTC, miR-146 and KIT expression using qRT-PCR. As shown in Fig. 6D -F, the expression CTC and KIT was downregulated and the expression of miR-146 was upregulated in PTC tissues compared with corresponding adjacent nontumorous tissues (ANT). Moreover, the ROC curves illustrated strong separation between the PTC patients and adjacent nontumorous tissues (ANT) (Supporting Fig. 5 ). Correlation analysis indicated that high level CTC expression was positively correlated with high levels of KIT ( Fig. 6G-I) . By contrast, an inverse correlation was observed between Scientific RepoRtS | (2020) 10:4616 | https://doi.org/10.1038/s41598-020-61577-z www.nature.com/scientificreports www.nature.com/scientificreports/ upregulated miR-146 expression and downregulated CTC and KIT expression ( Fig. 6G-I) . Taken together, those results provide evidence that CTC/miR-146/KIT axis might contribute to the progression of thyroid cancer.
Discussion
In the present study, for the first time, we described a novel signaling pathway mediating the migration and invasion of PTC cells. In this signaling pathway, CTC suppressed the migration and invasion of PTC cells. Mechanistic studies demonstrated that CTC interacts with miR-146, leading to disrupting miR-146 binding to the 3′-UTR of KIT. In addition, the CTC/miR-146/KIT axis regulated PTC chemoresistance.
Human miR-146 genes have two members, miR-146a and miR-146b, located on chromosomes 5 and 10, respectively 30 . Although miR-146a and miR-146b are encoded by different chromosomes, there are only two www.nature.com/scientificreports www.nature.com/scientificreports/ nucleotides that differ between the 3′ end of miR-146a and miR-146b 31 . According to limited structural differences, miR-146a and miR-146b are predicted to bind the 3′-UTR of the same genes. A previous study showed miR-146a function in inflammatory cytokine production and stem cell generation 32 . Importantly, several studies confirmed that miR-146a and miR-146b in PTC tissues could be a useful biomarker of the molecular diagnosis of PTC 25, 26 . Increasing numbers of studies suggest that lncRNAs functioned as an miRNA sponge to regulate cancer development 33 . In this study, accordance with bioinformatics prediction, we found lncRNA-CTC is a potential target of miR-146. Further luciferase reporter and RNA-pull down assays confirmed that CTC sponged miR-146 to derepress PTC cell proliferation and invasion. Interestingly, CTC regulated miR-146 expression, but miR-46 did not in turn regulate CTC expression, suggesting that miR-146 is a downstream molecule in CTC-mediated signaling. In clinical samples, an inverse correlation was observed in CTC and miR-146 levels. These clinical samples further support our conclusion that there is a target relationship between CTC and miR-146. Because all clinical samples were collected at one hospital, more PTC tissues should be investigated to compensate for this limitation and strengthen the robustness of this clinical finding. MiR-146 is a key modulator of the immune response 32 ; however, it remains unclear as to whether CTC participated in the immune response via miR-146. Illuminating the role of CTC in immune system could help further clarify the role of CTC function.
KIT, a member of the type III receptor tyrosine kinase family, is a tyrosine kinase receptor 34 . Downstream pathways include the MAPK and RAS and PI3-K/AKT cascades. KIT functions as an oncogene in many cancers 35 . A previous study report that miR-146 was upregulated in PTC tissues, and it regulated PTC progression by binding the 3′-UTR of KIT 25 . The activity of KIT is a hallmark in PTC; however, its biological significance remains unknown. We found that CTC regulated KIT expression via miR-146. We also found that CTC inhibited PTC cell migration and invasion via directly binding miR-146. However, we believe that this mechanism is the tip of the iceberg. One lncRNA could sponge several miRNAs simultaneously. Similarly, one miRNA can have several potential target genes. In other words, the CTC/miR-146/KIT axis may not be the only pathway targeted by CTC in PTC. Although further studies are needed to explore the potential miRNAs for CTC, we nevertheless believe that CTC might be a candidate biomarker for the progression of PTC. We also believe that interruption of CTC/ miR-146-KIT signaling might point the way toward suppression PTC progression.
We proposed a working model of the role of CTC in the proliferation and invasion of PTC cells (Fig. 7 ). In this model, miR-146 promotes PTC migration and invasion by targeting KIT 3′-UTR (Fig. 7A ). However, CTC regulates proliferation and chemoresistance in PTC cells by interacting with miR-146 ( Fig. 7B) . As a result, miR-146 cannot target the 3′-UTR of KIT or inhibit KIT expression ( Fig. 7B ). Subsequently, KIT inhibits proliferation and chemoresistance in PTC cells (Fig. 7B ). Our findings suggest efficient therapeutic approaches for PTC treatment. Samples and cases. PTC samples and adjacent nontumorous tissues (ANT) (located >3 cm away from the tumor) were collected from 125 patients who undergoing surgery at Gannan Medical University and Nanjing University of Chinese Medicine from April 2010 to April 2019. Two certified pathologists independently examined all PTC tissues to confirm histological subtype. ANT were confirmed by not being contaminated by cancer cells. Major inclusion criteria were as follows: (1) patients with pathologically confirmed PTC and without other malignancies; (2) patients that had not received any preoperative treatment; and (3) patients with complete clinical data, including age, sex, race, tumor size, and local invasion. Exclusion criteria were as follows: (1) patients with other kind of malignant tumors; (2) patients who were diagnosed with malignant lymphoma, poorly differentiated and anaplastic carcinomas; and (3) patients with stroke, organ transplantation, heart failure.
Tissue samples were divided into two parts. One part was used for the histologic diagnosis by two independently expert pathologists. The other part was stored in liquid nitrogen for RNA extraction. Tumors were staged according to the American Joint Committee on Cancer (AJCC) pathologic tumor-node metastasis (TNM) classification. The characteristics of patients are described in Supporting Table 1 . Five normal thyroid tissues, identified as normal tissues on histological examination, were collected from the contralateral thyroid lobe of patients with benign disease. cell and reagents. All human papillary thyroid cancer cell lines, including KTC-1, K1, KAT-5, K2, TPC-1, BCPAP, and BHP5-16, were purchased from Cell Bank of the Chinese Academy of Science (Wuhan, China). All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Grand Island, NY) containing with fetal bovine serum (Gibco BRL, Grand Island, NY) (10%), penicillin (100 U/mL) and streptomycin sulfate (100 µg/mL). Cells were maintained at 37 °C in a humidified atmosphere of 5% CO 2 and 95% air.
TRIzol, Lipofectamine-3000, and Enzyme MIX were purchased from Invitrogen (Basel, Switzerland). Monoclonal antibodies (Abs) against human KIT (ab32363, 1:1000), β-actin (ab8226, 1:5000) and GAPDH (ab181602,1:5000) were purchased from Abcam. SiRNAs and negative control (siRNA-control) were purchased from Qiagen (Germany). Efficiency of RNA interferences was determined using qRT-PCR or western migration (left panel) or invasion (right panel) assays. (I) Experiments were performed similar to those in (H), except indicated siRNA-ctrl or siRNA-KIT were used. (J,K) Experiments were performed similar to those in (H,I), except indicated siRNA-ctrl or siRNA-lncRNA CTC were used. All experiments were repeated at least three times with similar results. Bar graphs present means ± SD, n = 3 (**P < 0.01; *P < 0.05).
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(2020) 10:4616 | https://doi.org/10.1038/s41598-020-61577-z www.nature.com/scientificreports www.nature.com/scientificreports/ blotting analyses ( Fig. 4E and Supplementary Fig. 3 ). MiR-146 precursor (Pre-miR-146), miR-146 oligonucleotide (anti-miR-146), and its corresponding control (pre-control and anti-control) were purchased from Ambion (Austin, TX, USA). Unless specified otherwise, all biochemical reagents were purchased from Sigma-Aldrich (St. Louis, MI).
Tumor formation in nude mice. For each male BALB/c nude mouse (Ten 6-week-old), approximately 2×10 6 shRNA-Ctrl cells and siRNA-CTC cells were injected into the scapulae. The tumor volume was measured every 3 days by calculating tumor width and length. The formula was as follows: tumor volume = 1/2 length × cell proliferation assays. Cell proliferation activity was determined by using the Cell Counting Kit-8 (CCK-8) in accordance with the manufacturer's instructions (Dojindo Chemical Laboratory, Kumamoto, Japan). The absorbance (450 nm) were quantified by Power Wave XS microplate reader (Omega Bio-Tek, Inc., Norcross, GA, USA). Each group has five replicates. All experiments were independently repeated three times.
Migration and invasion assays. Migration and invasion assays were performed as described 36 . Briefly, cells were collected and plated the upper chamber (Corning) coated with (invasion) or without (migration) Matrigel-coated membrane matrices (BD Biosciences). The lower chamber was added medium with 10% FBS. Twenty-four hours later, cells were fixed with 4% formaldehyde and stained with crystal violet (Merck, Darmstadt, Germany). Cells were counted under a microscope (Olympus, Tokyo, Japan) at 200x magnification. The number of cells was the average value from six representative fields.
Transfection and luciferase reporter gene assays. Cells were grown to 80% confluence prior to transfection using Lipofectamine 3000 in accordance with the manufacturer's instructions (Invitrogen). Twenty-four hours later, cells were serum-starved for other 24 hours. Luciferase activity was measured using a dual-specific luciferase assay kit (Promega) (Madison, WI), and Renilla luciferase activities was used as internal control. 
